Moffitt Cancer Center Cell Coast Conference 2025

Advanced Cellular Therapy, CAR-T, Bispecific Antibodies & Immuno-Oncology Update

The Moffitt Cancer Center Cell Coast Conference 2025 is a premier educational event dedicated to the rapidly evolving field of cellular cancer therapies and next-generation immuno-oncology. Bringing together leading clinicians, researchers, and industry innovators, this conference provides an in-depth review of emerging cellular therapies, advanced engineering technologies, novel therapeutic targets, and cutting-edge treatment strategies transforming modern cancer care.

Held on October 17–18, 2025, the second annual Cell Coast Conference focuses on the latest advances in CAR-T cell therapy, bispecific antibodies, tumor-infiltrating lymphocyte (TIL) therapy, engineered immune cells, cellular therapy logistics, toxicity management, and translational oncology research.

Through expert-led presentations, multidisciplinary discussions, interactive debates, and real-world clinical insights, participants gain practical knowledge on the development, implementation, and optimization of cellular therapies across hematologic malignancies and solid tumors.

Product Details

• Format: 23 Videos (.MP4) + 23 Audios (.MP3) + 23 Subtitle Files (.VTT) + 21 PDFs
• Total Size: 13.2 GB
• Course Dates: October 17–18, 2025
• Access: On-Demand
• Level: Advanced
• Institution: Moffitt Cancer Center

Program Overview

Cellular therapies are revolutionizing oncology by offering highly targeted and potentially curative treatment options for patients with advanced cancers.

This conference explores:

• CAR-T cell therapies
• Bispecific antibodies (BiTEs)
• Tumor-infiltrating lymphocyte (TIL) therapy
• Cellular engineering innovations
• Immune cell modification strategies
• Novel therapeutic targets
• Hematologic malignancies
• Solid tumor immunotherapy
• Toxicity management
• Treatment sequencing
• Clinical implementation and logistics

The curriculum emphasizes practical clinical application while highlighting emerging research that is shaping the future of cellular oncology.

Learning Objectives

Upon completion of this activity, participants will be able to:

• Evaluate efficacy and toxicity management strategies for bispecific antibody therapies.
• Apply current evidence regarding CAR-T therapy for hematologic and solid malignancies.
• Analyze emerging in-vivo and armored CAR-T technologies.
• Review operational and logistical considerations for cellular therapy programs.
• Assess the evolving role of TIL therapy in solid tumors.
• Compare CAR-T and bispecific antibody approaches in hematologic cancers.
• Identify biomarkers associated with therapeutic response and toxicity.
• Develop multidisciplinary approaches to optimize patient outcomes.
• Improve referral pathways between community oncologists and cellular therapy centers.
• Integrate next-generation cellular therapies into clinical practice.

Core Topics Covered

CAR-T Cell Therapy

A major focus of the conference is the continued evolution of CAR-T therapy.

Topics include:

• CD19-directed CAR-T therapies
• CAR-T for acute lymphoblastic leukemia (ALL)
• CAR-T for lymphoma
• CAR-T for multiple myeloma
• CAR-T in solid tumors
• Armored CAR-T platforms
• In-vivo CAR-T technologies
• Future CAR-T innovations

Faculty review clinical outcomes, patient selection, and emerging research directions.

Bispecific Antibodies (BiTEs)

Sessions explore the rapidly expanding role of bispecific immunotherapies.

Key topics include:

• Non-Hodgkin lymphoma
• Multiple myeloma
• T-cell engaging antibodies
• Tarlatamab implementation
• Clinical efficacy data
• Safety considerations
• Cytokine release syndrome management

Participants gain practical guidance on incorporating these therapies into oncology practice.

Tumor-Infiltrating Lymphocyte (TIL) Therapy

The conference reviews advances in:

• TIL manufacturing
• Lung cancer applications
• Bladder cancer therapies
• Solid tumor immunotherapy
• Cellular expansion technologies
• Clinical trial updates

Experts discuss the growing role of TIL therapy within modern immuno-oncology.

Novel Targets & Emerging Approaches

Dedicated sessions highlight:

• New immunologic targets
• Next-generation cellular constructs
• Multi-antigen targeting strategies
• Tumor microenvironment modulation
• Precision cellular therapies
• Combination immunotherapy approaches

These discussions provide insight into future directions of cancer treatment.

Advanced Cellular Engineering

Participants review:

• Genetic engineering technologies
• Immune cell modification
• Enhanced persistence strategies
• Cellular fitness optimization
• Synthetic biology applications

Faculty explore how engineering innovations are improving treatment efficacy and durability.

Toxicity Management & Biomarkers

A critical component of cellular therapy practice involves identifying and managing treatment-related toxicities.

Topics include:

• Cytokine release syndrome (CRS)
• Immune effector cell-associated neurotoxicity syndrome (ICANS)
• Biomarker development
• Toxicity prediction
• Risk stratification
• Monitoring protocols

Practical management strategies are emphasized throughout the program.

CAR-T vs Bispecific Antibodies

Interactive debates examine:

• Treatment sequencing
• Comparative efficacy
• Safety profiles
• Cost considerations
• Accessibility challenges
• Clinical decision-making

Participants gain valuable perspectives on selecting optimal therapies for individual patients.

Clinical Operations & Program Development

The conference also addresses:

• Referral pathways
• Multidisciplinary care models
• Treatment logistics
• Program implementation
• Patient coordination
• Cellular therapy infrastructure

Special emphasis is placed on improving collaboration between referring oncologists and cellular therapy centers.

Educational Features

✔ Comprehensive Cellular Therapy Review

✔ CAR-T Therapy Updates

✔ Bispecific Antibody Advances

✔ Tumor-Infiltrating Lymphocyte (TIL) Therapy

✔ Novel Immunotherapy Targets

✔ Cellular Engineering Innovations

✔ Interactive Clinical Debates

✔ Practical Implementation Strategies

Target Audience

This course is ideal for:

• Hematologists
• Medical Oncologists
• Cellular Therapy Specialists
• Bone Marrow Transplant Physicians
• Advanced Practice Providers
• Oncology Pharmacists
• Oncology Nurses
• Immunotherapy Researchers
• Community Oncologists
• Clinical Trial Investigators
• Cancer Center Leadership Teams

Why This Course Stands Out

✔ Dedicated focus on next-generation cellular therapies

✔ Comprehensive coverage of CAR-T, BiTEs, and TIL therapies

✔ World-renowned oncology and cellular therapy faculty

✔ Strong emphasis on practical implementation

✔ Advanced discussions on cellular engineering and innovation

✔ Interactive debates on controversial treatment topics

✔ Bridges academic research and clinical application

✔ Valuable for both specialists and referring providers

Clinical & Educational Value

The Moffitt Cancer Center Cell Coast Conference 2025 delivers a comprehensive review of the rapidly expanding field of cellular oncology. Through expert-led discussions on CAR-T therapies, bispecific antibodies, TIL therapy, toxicity management, and future immunotherapy innovations, participants gain the knowledge needed to navigate one of the most transformative areas in modern cancer treatment.

This program serves as an essential resource for clinicians seeking to remain at the forefront of precision oncology, cellular immunotherapy, and advanced cancer care.

4. Topics

1. Bispecific Antibody Therapy in Non-Hodgkin Lymphoma and Toxicity Management

2. Operationalization of Tarlatamab Therapy at Moffitt Cancer Center

3. Bispecific Antibody Therapy for Relapsed Refractory Multiple Myeloma

4. Keynote Speaker Combination CAR T and anti-IFNG Strategies for the Management of Advanced Cancers

5. Novel Cellular Therapies for Sarcoma

6. CAR-T Cell Updates in ALL

7. GPC3 CAR T Cells for the Management of Advanced Cancers

8. CAR-T for Autoimmune Diseases

9. Biomarkers for Toxicity and Response in CAR-T for Multiple Myeloma

10. In-Vivo CAR-T

11. Claudin 18.2 for Gastrointestinal Malignancies

12. T Cell Fitness What’s Next after BCMA CAR

13. Armored CAR-T Strategies for Advanced Cancers

14. Allogeneic “off the shelf” IO approaches for MDS AML

15. CAR-NK Strategies for the Management of Advanced Cancers

16. Bladder Til Trial

17. Future of TIL Therapy

18. Novel TIL Therapies in Lung Cancer

19. CAR-T for Glioblastoma

20. GCC19 CAR T Trial

21. Practical Logistics of Clinical Care for Cell Therapy Patients

22. CAR-T vs BiTEs for Hematologic Malignancies (Part 1)

23. CAR-T vs BiTEs for Hematologic Malignancies (Part 2)